trending Market Intelligence /marketintelligence/en/news-insights/trending/_8kXsH-PJG4kTTAj3auBSQ2 content esgSubNav
In This List

Astellas' Suglat approved for type 1 diabetes mellitus in Japan

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Astellas' Suglat approved for type 1 diabetes mellitus in Japan

SNL Image

SNL Image

Astellas Pharma Inc. said its Suglat tablets have been approved in Japan for treating type 1 diabetes mellitus.

The drug was granted Japanese marketing approval for treating type 2 diabetes mellitus in January 2014.

People with diabetes have abnormally high blood sugar levels. In type 1 diabetes, the patient's body does not produce insulin — a hormone needed to keep blood sugar levels in check — while in type 2 diabetes, patients do not respond to insulin as well as they should.

Suglat was discovered through a collaboration between Tokyo's Astellas and Hanishina, Japan-based Kotobuki Pharmaceutical Co. Ltd.